Summary of Recent Legal Acts
The following legal acts represent key regulatory updates within the European Union, focusing on the standardization of financial research, international health product alignment, and carbon market synchronization.
1. Commission Delegated Regulation (EU) 2026/1092: Issuer-Sponsored Research
This Regulation establishes a mandatory, EU-wide “gold standard” for investment research funded by the companies being analyzed. It introduces a harmonized Code of Conduct aimed at eliminating conflicts of interest and restoring investor trust. Key provisions include the requirement for an “issuer-sponsored” label on all research, a prohibition on issuers reviewing draft recommendations for anything other than factual accuracy, and the mandatory public disclosure of revenue dependencies if issuer payments exceed 5% of a provider’s gross income. Investment firms act as gatekeepers, carrying strict legal liability for ensuring any distributed research adheres to these independence and transparency benchmarks.
2. Decision No 1/2026 (EU-Monaco Joint Committee): Health Products Alignment
This Decision updates the 2003 bilateral agreement between the EU and the Principality of Monaco regarding health products. It replaces the previous regulatory list with a modernized framework, incorporating current EU standards for medicinal products, cosmetics, and medical devices (including the integration of the AI Act). By aligning Monaco’s regulatory environment with the latest EU Regulations (EU) 2017/745 and 2017/746, the act facilitates the seamless movement of health goods and ensures that future EU legislative updates in these sectors apply automatically within the Principality.
3. Decision No 1/2026 (EU-Swiss Joint Committee): Emissions Trading System (ETS)
This Decision updates the technical Annex to the EU-Switzerland Agreement on the linking of their respective greenhouse gas emissions trading systems. The act mandates that Switzerland adopt the EU’s sharpened climate targets, specifically adjusting its Linear Reduction Factor (LRF) to 6.4% in 2025 to align with the EU’s trajectory of 4.3%–4.4% reduction per year. It reinforces strict market oversight criteria—mirroring EU MiFID II and Market Abuse Regulations—and mandates consistent monitoring and verification standards for both stationary industrial installations and the aviation sector to prevent competitive distortions.
Review of each of legal acts published today:
Commission Delegated Regulation (EU) 2026/1092 of 21 May 2026 supplementing Directive 2014/65/EU of the European Parliament and of the Council with regard to regulatory technical standards for the establishment of an EU code of conduct for issuer-sponsored research
Commission Delegated Regulation (EU) 2026/1092 establishes a harmonized EU code of conduct for “issuer-sponsored research,” which is investment research paid for by the company being analyzed. The act aims to restore trust in such research—particularly for small and medium-sized enterprises (SMEs)—by mandating strict independence, transparency, and conflict-of-interest management. It ensures that investors can clearly distinguish between independent analysis and sponsored content, while setting rigorous standards for research providers to prevent the issuer from influencing the research outcome.
### Structure and Main Provisions
The Regulation is structured as a primary legal text supported by a detailed Annex containing the “EU Code of Conduct.”
* **Core Definitions:** It defines “issuer-sponsored research,” “research analyst,” and “research provider,” explicitly excluding trading commentary or bespoke advisory services from the scope of this specific label.
* **Compliance Obligations:** Investment firms are legally responsible for verifying that any research they distribute under this label complies with the Code. They may rely on third-party audits or the regulated status of the provider, but the ultimate liability remains with the firm.
* **The Code of Conduct (Annex):** This is the heart of the act, detailing:
* **Conflict Management:** Requirements for maintaining a conflict-of-interest register and policy.
* **Operational Independence:** Strict rules on physical separation, prohibition of issuer review of draft recommendations, and insulation of analysts from commercial solicitation.
* **Transparency:** Mandatory disclosure of the sponsored nature of the research, payment structures, and potential revenue dependencies.
* **Contractual Integrity:** Minimum two-year contract terms and prohibitions on early termination based on dissatisfaction with the research’s content or recommendations.
Compared to previous fragmented national approaches, this Regulation creates a uniform “gold standard” across the EU, replacing disparate national rules with a single, enforceable framework.
### Key Provisions for Practical Application
For market participants, the following provisions are the most critical for daily operations:
1. **Mandatory Disclosure (Clause 4):** Research providers must prominently display the “issuer-sponsored” label on every page. They must also disclose if the issuer’s payments represent more than 5% of their gross revenue, which serves as a vital red flag for investors regarding potential bias.
2. **Independence Safeguards (Clause 3):** The prohibition on issuers reviewing draft research (except for factual accuracy) and the requirement that analysts remain insulated from commercial negotiations are the primary tools to prevent “pay-to-play” scenarios.
3. **Public Access (Clause 6):** If an issuer pays for the research in full, it must be made accessible to the public free of charge. This is a significant move to democratize information for retail investors.
4. **Record Keeping (Clause 9):** Providers must retain all agreements, payment records, and conflict-of-interest logs for at least five years, ensuring an audit trail is available for regulators and investment firms.
5. **Responsibility of Investment Firms (Article 2):** Investment firms are effectively the “gatekeepers.” If they cannot verify that the research meets the Code’s standards, they are strictly prohibited from distributing it under the “issuer-sponsored” label.
**:** This Regulation is highly relevant for the European financial market, including entities operating in or with Ukraine, as it harmonizes the standards for investment research across the EU. For Ukrainian financial institutions or analysts seeking to align with EU standards or provide services to EU-based clients, adherence to these strict transparency and independence requirements will be a prerequisite for operating within the European single market.
Decision No 1/2026 of the EU-Monaco Joint Committee established by the agreement between the European Community and the Principality of Monaco on the application of certain Community acts on the territory of the Principality of Monaco of 28 July 2026 amending the Annex to that Agreement [2026/1964]
Decision No 1/2026 of the EU-Monaco Joint Committee is a formal legal instrument that updates the regulatory alignment between the European Union and the Principality of Monaco regarding health products. Its primary purpose is to incorporate the latest Union legislation—specifically concerning medical devices, in vitro diagnostic medical devices, and medicinal products—into the Annex of the existing 2003 Agreement. By doing so, it ensures that the Principality maintains a harmonized regulatory framework with the EU, guaranteeing high standards of safety and health protection for products circulating within its territory.
**Structure and Main Provisions**
The Decision is structured into two main articles and a comprehensive Annex. Article 1 mandates the complete replacement of the previous Annex to the 2003 Agreement with an updated list of EU legal acts. Article 2 establishes the immediate entry into force of the Decision upon its adoption. The Annex itself is divided into three distinct sections:
1. **Medicines:** A detailed list of directives and regulations covering human and veterinary medicinal products, pharmacovigilance, clinical trials, and good manufacturing practices.
2. **Cosmetic Products:** A list of regulations governing the safety, composition, and labeling of cosmetics, including recent amendments regarding specific chemical substances.
3. **Medical Devices:** A list of acts covering medical devices and in vitro diagnostic medical devices, now updated to include the latest EU regulatory framework and the integration of the Artificial Intelligence Act as it pertains to these devices.
Compared to the previous 2013 version, this update is significant because it reflects the EU’s fundamental reform of the health product sector, moving from older directives to the more stringent and modern Regulations (EU) 2017/745 and (EU) 2017/746.
**Key Provisions for Implementation**
For practitioners and regulatory bodies, the following elements are of particular importance:
* **Regulatory Modernization:** The inclusion of the new medical device regulations ensures that Monaco’s market remains synchronized with the EU’s “robust regulatory framework,” which is essential for the free movement of these goods.
* **Operational Clarity:** The Decision explicitly addresses and seeks to resolve previous administrative difficulties regarding joint inspections of production facilities and laboratories conducted by Monegasque and French authorities.
* **Scope Limitation:** It is explicitly stated that this Decision does not expand the scope of the original 2003 Agreement nor grant new rights, serving strictly as an updating mechanism for the technical annex.
* **Automatic Application:** The text reinforces that, under Article 1(2) of the original Agreement, any future acts of the European Commission adopted in application of these listed acts will apply in Monaco automatically, without requiring further Joint Committee decisions.
This alignment is vital for maintaining seamless trade and safety standards in the health sector between the EU and Monaco.
Decision No 1/2026 of the Joint Committee established by the Agreement between the European Union and the Swiss Confederation on the linking of their greenhouse gas emissions trading systems of 9 June 2026 as regards the amendment of Annex I to the Agreement [2026/1993]
Decision No 1/2026 of the Joint Committee represents a formal update to the bilateral agreement between the European Union and the Swiss Confederation regarding the linking of their respective greenhouse gas emissions trading systems (ETS). The primary objective of this act is to ensure that the Swiss ETS remains fully compatible with the EU ETS following significant legislative revisions within the Union. By updating Annex I, the Decision maintains market integrity and prevents distortions of competition between the two linked systems.
### Structure and Main Provisions
The act is structured as a formal legal decision comprising two articles and a comprehensive Annex.
* **Article 1** serves as the operative provision, replacing the existing Parts A and B of Annex I to the Agreement with updated text.
* **Article 2** establishes the immediate entry into force of the Decision.
* **The Annex** acts as the technical core of the document, detailing the “Essential Criteria” for both stationary installations and the aviation sector.
Compared to previous versions, this update incorporates the regulatory changes stemming from Directives (EU) 2023/958 and (EU) 2023/959, which align the EU ETS with the target of a 55% reduction in greenhouse gas emissions by 2030. It updates the references to EU and Swiss legislation to reflect the legal framework in force as of 1 January 2025.
### Key Provisions for Practical Application
For those monitoring or operating within these systems, the following provisions are of critical importance:
1. **Linear Reduction Factors (LRF):** The Decision codifies the LRF for the cap on emissions. For the EU, this is set at 4.3% per year (2024–2027) and 4.4% from 2028. Switzerland has adjusted its LRF to 6.4% for 2025 to ensure alignment with the EU’s reduction trajectory, transitioning to the same 4.3%/4.4% schedule thereafter.
2. **Aviation Sector Integration:** The Annex provides detailed criteria for aviation, including the “departing flight principle.” It clarifies the administration of aircraft operators, ensuring that Switzerland acts as an “Administering Member State” for specific operators, while maintaining a “one-stop shop” approach to compliance and reporting to prevent double counting.
3. **Market Oversight and Benchmarking:** The act mandates that market oversight in Switzerland must be as stringent as the EU’s MiFID II/MiFIR and Market Abuse Regulation frameworks. Furthermore, it updates the specific benchmark values for the free allocation of allowances to aircraft operators for the years 2024 and 2025, ensuring that the Swiss system does not provide more favorable conditions than the EU system.
4. **Monitoring, Reporting, and Verification (MRV):** The Decision reinforces that MRV requirements for both stationary installations and aviation must meet the high standards of EU Implementing Regulations (EU) 2018/2066 and 2018/2067, ensuring data consistency across the linked markets.
This update is essential for maintaining the legal and operational synchronization of the two systems, ensuring that carbon pricing remains consistent across the European and Swiss markets.
